OncoMatch/Clinical Trials/NCT04698252
Local Therapy for ER/PR-positive Oligometastatic Breast Cancer
Is NCT04698252 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
Estrogen receptor-positive and/ or progesterone receptor-positive breast cancer
Required: PR (PGR) positive
Estrogen receptor-positive and/ or progesterone receptor-positive breast cancer
Excluded: HER2 (ERBB2) positive
HER2-positive breast cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic therapy
Partial response or stable disease after at least six months of systemic therapy for breast cancer
Cannot have received: local therapy for distant metastasis
Previous local therapy for distant metastasis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04698252 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior local therapy for distant metastasis disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 positive is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR positive is a required biomarker for enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 positive is an exclusion criterion.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify